Original from: 360dx

Home testing firm Imaware announced on Monday that it has acquired Binx Health's at-home consumer testing business for an undisclosed amount.

The acquisition is intended to expand Imaware's position in the home health testing market and broaden the number of enterprise clients serviced by Imaware, the company said in a statement. 

Binx Health will retain its point-of-care molecular diagnostic business. The Binx IO platform has received approval from the US Food and Drug Administration and CLIA waiver to detect chlamydia and gonorrhea in vaginal swab specimens and male urine samples. 

The Binx business "fits perfectly into our high growth plans for the coming years," Imaware Cofounder Jani Tuomi said in a statement. 

Imaware offers home-based tests for a variety of conditions, including autoimmune diseases, coronavirus, and allergic diseases.

Source: Imaware Acquires Binx Health At-Home Consumer Testing Business